Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

被引：83

作者：

Loren, A. W. ^{[1
]}

Porter, D. L. ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Bone Marrow & Stem Cell Transplant Program, Philadelphia, PA 19104 USA

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 41卷 / 05期

关键词：

acute leukemia; graft-versus-leukemia; donor lymphocyte infusions;

D O I：

10.1038/sj.bmt.1705898

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with acute leukemia. Unfortunately, many patients relapse and die of their disease even after transplantation. Although in some cases, allogeneic SCT is effective because the intensive conditioning therapy eradicates all malignant cells, it has long been recognized that the adoptive transfer of donor immunity plays a critically important role in the induction and maintenance of remission. Recognition of the graft-versus-leukemia (GVL) effect of allogeneic SCT has prompted attempts at remission re-induction by adoptive immunotherapy with donor lymphocyte infusions (DLIs) in patients with relapsed disease after allogeneic SCT. In some cases, DLI-induced remissions are sustained and patients cured when no other treatment modality was effective. This review discusses the rationale, biology, complications and future applications of DLI in acute leukemia patients after allogeneic SCT.

引用

页码：483 / 493

页数：11

共 99 条

[21] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[22] Extramedullary sites of leukemia relapse after transplant [J].

Cunningham, Isabel .

LEUKEMIA & LYMPHOMA, 2006, 47 (09) :1754-1767

[23]

Dazzi F, 2000, BLOOD, V96, P2712

[24] Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease [J].

de Lima, M ;

Bonamino, M ;

Vasconcelos, Z ;

Colares, M ;

Diamond, H ;

Zalcberg, I ;

Tavares, R ;

Lerner, D ;

Byington, R ;

Bouzas, L ;

da Matta, J ;

Andrade, C ;

Carvalho, L ;

Pires, V ;

Barone, B ;

Maciel, C ;

Tabak, D .

BONE MARROW TRANSPLANTATION, 2001, 27 (01) :73-78

[25] Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation [J].

Dey, BR ;

McAfee, S ;

Colby, C ;

Sackstein, R ;

Saidman, S ;

Tarbell, N ;

Sachs, DH ;

Sykes, M ;

Spitzer, TR .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (05) :320-329

[26]

DROBYSKI WR, 1993, BLOOD, V82, P2310

[27] Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients [J].

Dudley, ME ;

Wunderlich, JR ;

Shelton, TE ;

Even, J ;

Rosenberg, SA .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :332-342

[28] Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes [J].

Falkenburg, JHF ;

Wafelman, AR ;

Joosten, P ;

Smit, WM ;

van Bergen, CAM ;

Bongaerts, R ;

Lurvink, E ;

van der Hoorn, M ;

Kluck, P ;

Landegent, JE ;

Kluin-Nelemans, HC ;

Fibbe, WE ;

Willemze, R .

BLOOD, 1999, 94 (04) :1201-1208

[29] Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor [J].

Figlin, RA ;

Pierce, WC ;

Kaboo, R ;

Tso, CL ;

Moldawer, N ;

Gitlitz, B ;

deKernion, J ;

Belldegrun, A .

JOURNAL OF UROLOGY, 1997, 158 (03) :740-745

[30] Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation [J].

Flowers, MED ;

Leisenring, W ;

Beach, K ;

Riddell, S ;

Radich, JP ;

Higano, CS ;

Rowley, SD ;

Chauncey, TR ;

Bensinger, WI ;

Sanders, JE ;

Anasetti, C ;

Storb, R ;

Wade, J ;

Appelbaum, FR ;

Martin, PJ .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (3A) :321-326

← 1 2 3 4 5 6 7 8 9 10 →